Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder (Q44466168)

3 December 2017

Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder (English)

1 reference

obsessive-compulsive disorder

3 December 2017

0 references

author name string

Giuseppina D'Amico

1

1 reference

3 December 2017

Clemente Cedro

2

1 reference

3 December 2017

Maria Rosaria Muscatello

3

1 reference

3 December 2017

Gianluca Pandolfo

4

1 reference

3 December 2017

Antonio Enrico Di Rosa

5

1 reference

3 December 2017

Rocco Zoccali

6

1 reference

3 December 2017

Diletta La Torre

7

1 reference

3 December 2017

Concetta D'Arrigo

8

1 reference

3 December 2017

Edoardo Spina

9

1 reference

3 December 2017

1 June 2003

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

3 December 2017

1 reference

3 December 2017

27

1 reference

3 December 2017

4

1 reference

3 December 2017

619-623

1 reference

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Interaction of olanzapine with fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

The Yale-Brown Obsessive Compulsive Scale. II. Validity

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Column liquid chromatographic determination of paroxetine in human serum using solid-phase extraction

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Treatment non-response in OCD: methodological issues and operational definitions

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Newer antipsychotics: comparative review of drug interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Clinically significant drug interactions with antidepressants in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2803%2900050-2

7 January 2021

10.1016/S0278-5846(03)00050-2

Identifiers

DOI

1 reference

3 December 2017

1 reference